GUFICBIO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Gufic Biosciences Invests AED 200,000 In Unit Veira Life
Jan 13 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD - GUFIC BIOSCIENCES INVESTS AED 200,000 IN UNIT VEIRA LIFE FZE
Source text: ID:nBSE1j770C
Further company coverage: GUFI.NS
(([email protected];))
Jan 13 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD - GUFIC BIOSCIENCES INVESTS AED 200,000 IN UNIT VEIRA LIFE FZE
Source text: ID:nBSE1j770C
Further company coverage: GUFI.NS
(([email protected];))
India's Gufic Biosciences falls on Q2 profit drop
** Shares of Gufic Biosciences GUFI.NS slip 6.1% to 418.50 rupees
** The pharmaceuticals co's Q2 consol total profit fell 6.2% y/y, revenue down 5% y/y
** Strategic initiatives,including increase in overall market share in Botulinum Toxin products, investments in new biological technology platform and commercialization of immuno-oncology therapy to boost growth over next few years, co says
** Stock up ~32% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Gufic Biosciences GUFI.NS slip 6.1% to 418.50 rupees
** The pharmaceuticals co's Q2 consol total profit fell 6.2% y/y, revenue down 5% y/y
** Strategic initiatives,including increase in overall market share in Botulinum Toxin products, investments in new biological technology platform and commercialization of immuno-oncology therapy to boost growth over next few years, co says
** Stock up ~32% YTD
(Reporting by Vijay Malkar)
(([email protected];))
Gufic Biosciences Sept-Quarter Consol Total Profit 217.7 Mln Rupees
Nov 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
SEPT-QUARTER CONSOL TOTAL PROFIT 217.7 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.04 BILLION RUPEES
Source text: [ID:]
Further company coverage: GUFI.NS
(([email protected];;))
Nov 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
SEPT-QUARTER CONSOL TOTAL PROFIT 217.7 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.04 BILLION RUPEES
Source text: [ID:]
Further company coverage: GUFI.NS
(([email protected];;))
Gufic Biosciences June-Quarter Net Profit From Cont Ops 208.6 Mln Rupees
Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
JUNE-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 208.6 MILLION RUPEES
JUNE-QUARTER REVENUE FROM OPERATIONS 2.03 BILLION RUPEES
RE‐APPOINTMENT OF JAYESH CHOKSI AS CHAIRMAN, MD
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(Reporting by VijayDattaram Malkar)
(([email protected];))
Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
JUNE-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 208.6 MILLION RUPEES
JUNE-QUARTER REVENUE FROM OPERATIONS 2.03 BILLION RUPEES
RE‐APPOINTMENT OF JAYESH CHOKSI AS CHAIRMAN, MD
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(Reporting by VijayDattaram Malkar)
(([email protected];))
Gufic Biosciences Says Granted Patent For Invention
March 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION ENTITLED LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(([email protected];))
March 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION ENTITLED LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(([email protected];))
Gufic Biosciences Dec-Qtr Total Profit Rises
Feb 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES DEC-QUARTER TOTAL PROFIT 222.6 MILLION RUPEES VERSUS PROFIT 203.4 MILLION RUPEES
GUFIC BIOSCIENCES DEC-QUARTER REVENUE FROM OPERATIONS 2.02 BILLION RUPEES VERSUS 1.77 BILLION RUPEES
Source text for Eikon: ID:nBSE5KSK8Y
Further company coverage: GUFI.NS
(([email protected];;))
Feb 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES DEC-QUARTER TOTAL PROFIT 222.6 MILLION RUPEES VERSUS PROFIT 203.4 MILLION RUPEES
GUFIC BIOSCIENCES DEC-QUARTER REVENUE FROM OPERATIONS 2.02 BILLION RUPEES VERSUS 1.77 BILLION RUPEES
Source text for Eikon: ID:nBSE5KSK8Y
Further company coverage: GUFI.NS
(([email protected];;))
Gufic Biosciences Says Co Granted Patent Of Addition For Freeze Dried Parenteral Composition Of Omadacycline Tosylate
Jan 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
CO GRANTED PATENT OF ADDITION FOR FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE
GOT PATENT FOR 20 YEARS
Source text for Eikon: ID:nNSE1hr677
Further company coverage: GUFI.NS
(([email protected];))
Jan 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
CO GRANTED PATENT OF ADDITION FOR FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE
GOT PATENT FOR 20 YEARS
Source text for Eikon: ID:nNSE1hr677
Further company coverage: GUFI.NS
(([email protected];))
India's Gufic Biosciences Sept-Quarter Net Profit From Continuing Operations Rises
Nov 9 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES SEPT-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 232.1 MILLION RUPEES VERSUS 202.1 MILLION RUPEES
GUFIC BIOSCIENCES LTD SEPT-QUARTER REVENUE FROM OPERATIONS 2.15 BILLION RUPEES VERSUS 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSEbNyQpm
Further company coverage: GUFI.NS
(([email protected];))
Nov 9 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES SEPT-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 232.1 MILLION RUPEES VERSUS 202.1 MILLION RUPEES
GUFIC BIOSCIENCES LTD SEPT-QUARTER REVENUE FROM OPERATIONS 2.15 BILLION RUPEES VERSUS 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSEbNyQpm
Further company coverage: GUFI.NS
(([email protected];))
Gufic Biosciences Approves Incorporation Of Unit In Dubai, UAE
Sept 27 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UAE
Source text for Eikon: ID:nBSEcgCgsV
Further company coverage: GUFI.NS
(([email protected];;))
Sept 27 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UAE
Source text for Eikon: ID:nBSEcgCgsV
Further company coverage: GUFI.NS
(([email protected];;))
India's Gufic Biosciences rises on patent grant
** Shares of Gufic Biosciences GUFI.NS up as much as 4.57% to 310 rupees
** Stock on track for third consecutive session of gains
** Active pharmaceutical ingredients maker said it has been granted 20-year patent for Omadacycline Tosylate, a component used in drugs
** About 201,355 shares change hands as of 10:42 a.m. IST, 0.5x 30-day average
** Stock up ~31% so far this year, as of last close
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of Gufic Biosciences GUFI.NS up as much as 4.57% to 310 rupees
** Stock on track for third consecutive session of gains
** Active pharmaceutical ingredients maker said it has been granted 20-year patent for Omadacycline Tosylate, a component used in drugs
** About 201,355 shares change hands as of 10:42 a.m. IST, 0.5x 30-day average
** Stock up ~31% so far this year, as of last close
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
Gufic Biosciences Granted Patent For "Freeze Dried Parenteral Composition Of Omadacycline Tosylate, Process For Preparation Thereof"
Sept 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION "FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE AND PROCESS FOR PREPARATION THEREOF"
PATENT GRANTED FOR TERM OF 20 YEARS EFFECTIVE FROM APRIL 19, 2021
Source text for Eikon: ID:nBSE1rQVLF
Further company coverage: GUFI.NS
(([email protected];))
Sept 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GRANTED PATENT FOR INVENTION "FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE AND PROCESS FOR PREPARATION THEREOF"
PATENT GRANTED FOR TERM OF 20 YEARS EFFECTIVE FROM APRIL 19, 2021
Source text for Eikon: ID:nBSE1rQVLF
Further company coverage: GUFI.NS
(([email protected];))
India's Gufic Biosciences up on Australia, Brazil nod for parecoxib injection
** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to 319.2 rupees, biggest pct gain since July 27
** Co receives regulatory approval for Parecoxib 40 mg injection from Australia's TGA and Brazil's Anvisa
** Injection to be used for short-term treatment of acute pain and post-operative pain in adult patients
** More than 804,930 shares change hands by 11:20 a.m. IST, 2.0x the 30-day avg of 402,502 shares
** Stock last up 2.6%, bumping YTD gains to ~33%
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to 319.2 rupees, biggest pct gain since July 27
** Co receives regulatory approval for Parecoxib 40 mg injection from Australia's TGA and Brazil's Anvisa
** Injection to be used for short-term treatment of acute pain and post-operative pain in adult patients
** More than 804,930 shares change hands by 11:20 a.m. IST, 2.0x the 30-day avg of 402,502 shares
** Stock last up 2.6%, bumping YTD gains to ~33%
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Gufic Biosciences Receives TGA Australia And ANVISA Brazil Approval For Parecoxib 40Mg Injection
Sept 11 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC RECEIVES TGA AUSTRALIA AND ANVISA BRAZIL APPROVAL FOR PARECOXIB 40MG INJECTION
Source text for Eikon: ID:nBSE2z651g
Further company coverage: GUFI.NS
(([email protected];))
Sept 11 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC RECEIVES TGA AUSTRALIA AND ANVISA BRAZIL APPROVAL FOR PARECOXIB 40MG INJECTION
Source text for Eikon: ID:nBSE2z651g
Further company coverage: GUFI.NS
(([email protected];))
India's Gufic Biosciences jumps on Motilal investment
** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to a record high of 333 rupees
** Institutional investor Motilal Oswal Financial Services MOFS.NS to buy 3.32% stake in active pharmaceutical ingredients maker for 999.9 million rupees ($12.1 million)
** GUFI issues preferential shares to MOFS at 300 rupees per share
** Stock most active since June 16, with ~1.32 mln shares traded by 2:17 p.m. IST
** Stock set for best week since June 16; currently up over 14% this week
($1 = 82.7096 Indian rupees)
(Reporting by Nandan Mandayam in Bengaluru)
(([email protected]; Mobile: +91 9591011727;))
** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to a record high of 333 rupees
** Institutional investor Motilal Oswal Financial Services MOFS.NS to buy 3.32% stake in active pharmaceutical ingredients maker for 999.9 million rupees ($12.1 million)
** GUFI issues preferential shares to MOFS at 300 rupees per share
** Stock most active since June 16, with ~1.32 mln shares traded by 2:17 p.m. IST
** Stock set for best week since June 16; currently up over 14% this week
($1 = 82.7096 Indian rupees)
(Reporting by Nandan Mandayam in Bengaluru)
(([email protected]; Mobile: +91 9591011727;))
India's Gufic Biosciences hits over 1-yr high on China approval for API
** Shares of active pharmaceutical ingredients (API) maker Gufic Biosciences Ltd GUFI.NS up as much as 6.6% to 247 rupees, their highest since May 20, 2022
** Co on Friday said it received approval from National Medical Products Administration (NMPA), China, for Prilocaine API, an amide-type local anaesthetic
** Co says approval will help in commercialisation of the product in China and help explore Chinese market
** Over 654,000 shares change hands by 10:02 a.m. IST, 4.0x the 30-day moving avg
** As of last close, stock up 2.3% so far this year
(Reporting by Kashish Tandon in Bengaluru)
** Shares of active pharmaceutical ingredients (API) maker Gufic Biosciences Ltd GUFI.NS up as much as 6.6% to 247 rupees, their highest since May 20, 2022
** Co on Friday said it received approval from National Medical Products Administration (NMPA), China, for Prilocaine API, an amide-type local anaesthetic
** Co says approval will help in commercialisation of the product in China and help explore Chinese market
** Over 654,000 shares change hands by 10:02 a.m. IST, 4.0x the 30-day moving avg
** As of last close, stock up 2.3% so far this year
(Reporting by Kashish Tandon in Bengaluru)
Gufic Biosciences Received Approval From National Medical Products Administration, China For Product Prilocaine (API)
June 16 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
RECEIVED APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION, CHINA FOR PRODUCT PRILOCAINE (API)
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(([email protected];))
June 16 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
RECEIVED APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION, CHINA FOR PRODUCT PRILOCAINE (API)
Source text for Eikon: [ID:]
Further company coverage: GUFI.NS
(([email protected];))
Gufic Biosciences - Cleared Brazilian Health Regulatory Audit For Gujarat Plant
May 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD- CLEARED PHYSICAL AUDIT OF BRAZILIAN HEALTH REGULATORY AGENCY SUCCESSFULLY WITHOUT ANY OBSERVATION
GUFIC BIOSCIENCES LTD- RECEIVED GOOD MANUFACTURING PRACTICES CERTIFICATE FROM ANVISA FOR GUJARAT PLANT
GUFIC BIOSCIENCES LTD- WILL ENABLE CO TO EXPAND BUSINESS IN BRAZIL
Source text for Eikon: ID:nBSE94QRJp
Further company coverage: GUFI.NS
(([email protected];))
May 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
GUFIC BIOSCIENCES LTD- CLEARED PHYSICAL AUDIT OF BRAZILIAN HEALTH REGULATORY AGENCY SUCCESSFULLY WITHOUT ANY OBSERVATION
GUFIC BIOSCIENCES LTD- RECEIVED GOOD MANUFACTURING PRACTICES CERTIFICATE FROM ANVISA FOR GUJARAT PLANT
GUFIC BIOSCIENCES LTD- WILL ENABLE CO TO EXPAND BUSINESS IN BRAZIL
Source text for Eikon: ID:nBSE94QRJp
Further company coverage: GUFI.NS
(([email protected];))
India's Gufic Biosciences March-Qtr Net Profit From Cont Ops Falls
May 29 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES MARCH-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 181.1 MILLION RUPEES VERSUS PROFIT 202.6 MILLION RUPEES
GUFIC BIOSCIENCES MARCH-QUARTER REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.62 BILLION RUPEES
Further company coverage: GUFI.NS
(([email protected];;))
May 29 (Reuters) - Gufic Biosciences Ltd GUFI.NS:
INDIA'S GUFIC BIOSCIENCES MARCH-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 181.1 MILLION RUPEES VERSUS PROFIT 202.6 MILLION RUPEES
GUFIC BIOSCIENCES MARCH-QUARTER REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.62 BILLION RUPEES
Further company coverage: GUFI.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Gufic Biosciences do?
Gufic Biosciences Limited, a public company from India, specializes in manufacturing and marketing active pharmaceutical ingredients and generic pharmaceuticals.
Who are the competitors of Gufic Biosciences?
Gufic Biosciences major competitors are Orchid Pharma, Guj. Themis Biosyn, Unichem Lab, Zota Health Care, Panacea Biotec, Sequent Scientific, Indoco Remedies. Market Cap of Gufic Biosciences is ₹3,680 Crs. While the median market cap of its peers are ₹3,515 Crs.
Is Gufic Biosciences financially stable compared to its competitors?
Gufic Biosciences seems to be less financially stable compared to its competitors. Altman Z score of Gufic Biosciences is 5.98 and is ranked 4 out of its 8 competitors.
Does Gufic Biosciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Gufic Biosciences latest dividend payout ratio is 1.16% and 3yr average dividend payout ratio is 1.13%
How has Gufic Biosciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Accounts Receivable
How strong is Gufic Biosciences balance sheet?
Balance sheet of Gufic Biosciences is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Gufic Biosciences improving?
The profit is oscillating. The profit of Gufic Biosciences is ₹69.65 Crs for TTM, ₹86.14 Crs for Mar 2024 and ₹79.7 Crs for Mar 2023.
Is the debt of Gufic Biosciences increasing or decreasing?
The net debt of Gufic Biosciences is decreasing. Latest net debt of Gufic Biosciences is ₹281 Crs as of Mar-25. This is less than Mar-24 when it was ₹291 Crs.
Is Gufic Biosciences stock expensive?
Yes, Gufic Biosciences is expensive. Latest PE of Gufic Biosciences is 52.84, while 3 year average PE is 33.5. Also latest EV/EBITDA of Gufic Biosciences is 29.41 while 3yr average is 20.34.
Has the share price of Gufic Biosciences grown faster than its competition?
Gufic Biosciences has given better returns compared to its competitors. Gufic Biosciences has grown at ~23.31% over the last 8yrs while peers have grown at a median rate of 14.47%
Is the promoter bullish about Gufic Biosciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Gufic Biosciences is 72.51% and last quarter promoter holding is 72.51%.
Are mutual funds buying/selling Gufic Biosciences?
The mutual fund holding of Gufic Biosciences is increasing. The current mutual fund holding in Gufic Biosciences is 3.39% while previous quarter holding is 2.92%.